Achieve Life Sciences jumps on Hunterbrook Capital endorsement
Source: SeekingAlpha
2025-12-30 12:18:03 ET
More on Achieve Life Sciences
- Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript
- Achieve: Expedited Review Of Cytisinicline Sets The Stage For Development Expansion
- Achieve Life Sciences outlines expedited FDA review for cytisinicline and targets Q3/Q4 2026 launch
- Achieve Life Sciences Q3 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on Achieve Life Sciences
Read the full article on Seeking Alpha
For further details see:
Achieve Life Sciences jumps on Hunterbrook Capital endorsement
Achieve Life Sciences Inc.
NASDAQ: ACHV
ACHV Trading
2.79% G/L:
$5.52 Last:
404,475 Volume:
$5.10 Open:
ACHV Latest News
May 19, 2026 02:15:00 pm
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
May 12, 2026 07:05:00 am
Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma
May 12, 2026 07:00:00 am
Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates
ACHV Stock Data
$234,761,887
51,636,968
N/A
28
N/A
Biotechnology & Life Sciences
Healthcare
CA
Bothell
